Description

Successful drug discovery and development relies greatly on the availability of in vitro and in vivo models that can accurately represent a disease state and inform a clinical response. Many diseases have poor or no models, which is holding back research and drug discovery for those patients. Today, advancements in bioengineering have created a group of emerging, cell-based, 3D technologies that are improving the options for drug discovery and disease modeling. From bioprinting to recellularizing, we will discuss new technologies and how they are being used in R&D today and in the future. This panel will: - Evaluate the commercial readiness of new 3D technologies - Discuss how company’s are approaching integration of 3D technologies into drug discovery and development - Examine the current and future applications of 3D technologies in better researching human disease and identifying clinically relevant biomarkers - Learn about how FDA, NIH, and pharma are using 3D technologies

Key Takeaways:

  • Evaluate the commercial readiness of new 3D technologies and how they are being used in R&D
  • Discuss how companies are approaching integration of 3D technologies into drug discovery and development
  • Learn about how FDA, NIH, and pharma are using 3D technologies

Ability Level: Advanced

Session ID: 2422

myBIO Chatter
Educational Topics